Inspira Signs Agreement Expansion With Innovimed For Clinical Trials Of INSPIRA ART Respiratory Medical Devices
Portfolio Pulse from Happy Mohamed
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) has expanded its Service Agreement with Innovimed for clinical trials of the INSPIRA ART medical devices in any European country. This follows previous distribution agreements with Innovimed in Poland, Czech Republic, and Slovakia, potentially generating over $130 million in revenues over seven years.
August 29, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inspira Technologies has expanded its agreement with Innovimed for clinical trials of its medical devices in Europe. This could potentially generate over $130 million in revenues over seven years.
The expanded agreement with Innovimed allows Inspira to conduct clinical trials in any European country, broadening its market reach. The potential revenue from this expansion is significant, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100